Literature DB >> 26846106

Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma.

Donghui Ju1,2, Fumio Yamaguchi2, Guangzhi Zhan2, Tadashi Higuchi2, Takayuki Asakura2, Akio Morita2, Hideo Orimo3, Shaoshan Hu4.   

Abstract

Sonodynamic therapy (SDT) has shown great potential as an approach for cancer treatment, and hyperthermotherapy (HT) is also a promising cancer therapy. Here, we investigate whether HT could improve the efficacy of SDT and to make a preliminary exploration on potential mechanism. Xenograft tumor was established in nude mice model, and SNB19 and U87MG glioma cell lines were utilized for in vitro experiment. Alamar blue assay was performed to assess cell viability. Optical microscope was used to characterize the morphology changes of the glioma cells induced by SDT and HT treatments. Apoptotic rate, mitochondrial membrane potential (MMP), and intracellular production of reactive oxygen species (ROS) were examined by flow cytometer. The cell apoptosis of tumor tissues were detected by TUNEL assay. Furthermore, the expression of apoptosis-related proteins was detected with Western blot in vitro and immunohistochemistry in vivo. SDT plus HT group could significantly reduce the cell viability with circular-cell morphological change, compared with SDT group, and cell viability was decreased depending on raise of 5-ALA concentration, ultrasound exposure time, and temperature. The results also indicate that HT increased a conspicuous apoptosis, ROS production, and a remarkable loss in MMP induced by 5-ALA-SDT in vitro. Meanwhile, our data also demonstrated that the combined treatment could significantly induce apoptosis and delay tumor growth in vivo. Furthermore, in both in vitro and in vivo experiments, SDT plus HT group expressed significantly higher protein levels of Bax and cleaved caspase-3, 8, and 9 compared to SDT, HT, and control groups and significantly lower protein level of bcl-2 than the other three groups, while the expression of these proteins was unchanged between HT and control groups. HT may provide an important promotion on 5-ALA-SDT and further propose that SDT in combination with HT is a new potential application for the treatment of human glioma.

Entities:  

Keywords:  5-aminolevulinic acid; Antitumor effect; Apoptosis; Glioma; Hyperthermotherapy; Sonodynamic therapy

Mesh:

Substances:

Year:  2016        PMID: 26846106     DOI: 10.1007/s13277-016-4931-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Apoptosis of SAS cells induced by sonodynamic therapy using 5-aminolevulinic acid sonosensitizer.

Authors:  Wei Song; Haidong Cui; Rui Zhang; Jinhua Zheng; Wenwu Cao
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

Review 2.  Therapeutic hyperthermia: The old, the new, and the upcoming.

Authors:  Matthew Mallory; Emile Gogineni; Guy C Jones; Lester Greer; Charles B Simone
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-08       Impact factor: 6.312

3.  Relation between mitochondrial membrane potential and ROS formation.

Authors:  Jan M Suski; Magdalena Lebiedzinska; Massimo Bonora; Paolo Pinton; Jerzy Duszynski; Mariusz R Wieckowski
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Hyperthermia in oncology.

Authors:  M H Falk; R D Issels
Journal:  Int J Hyperthermia       Date:  2001 Jan-Feb       Impact factor: 3.914

5.  Combination of Protoporphyrin IX-mediated Sonodynamic Treatment with Doxorubicin Synergistically Induced Apoptotic Cell Death of a Multidrug-Resistant Leukemia K562/DOX Cell Line.

Authors:  Xiaobing Wang; Yali Jia; Xiaomin Su; Pan Wang; Kun Zhang; Xiaolan Feng; Quanhong Liu
Journal:  Ultrasound Med Biol       Date:  2015-07-10       Impact factor: 2.998

Review 6.  ALA and its clinical impact, from bench to bedside.

Authors:  Barbara Krammer; Kristjan Plaetzer
Journal:  Photochem Photobiol Sci       Date:  2007-12-07       Impact factor: 3.982

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  The safety and efficacy of magnetic nano-iron hyperthermia therapy on rat brain glioma.

Authors:  Guo-qing Yi; Bin Gu; Lu-kui Chen
Journal:  Tumour Biol       Date:  2013-10-28

9.  Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.

Authors:  J L Gross; D L Behrens; D E Mullins; P L Kornblith; D L Dexter
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

10.  Sinoporphyrin sodium, a novel sensitizer, triggers mitochondrial-dependent apoptosis in ECA-109 cells via production of reactive oxygen species.

Authors:  Haiping Wang; Xiaobing Wang; Shaoliang Zhang; Pan Wang; Kun Zhang; Quanhong Liu
Journal:  Int J Nanomedicine       Date:  2014-06-25
View more
  11 in total

Review 1.  Current status and future perspective of sonodynamic therapy for cancer.

Authors:  Atsushi Sofuni; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2022-10-12       Impact factor: 1.878

Review 2.  Sonodynamic therapy: Rapid progress and new opportunities for non-invasive tumor cell killing with sound.

Authors:  Katherine M Nowak; Mark R Schwartz; Victoria R Breza; Richard J Price
Journal:  Cancer Lett       Date:  2022-02-11       Impact factor: 9.756

Review 3.  Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives.

Authors:  Qing-Long Guo; Xing-Liang Dai; Meng-Yuan Yin; Hong-Wei Cheng; Hai-Sheng Qian; Hua Wang; Dao-Ming Zhu; Xian-Wen Wang
Journal:  Mil Med Res       Date:  2022-06-09

Review 4.  Emerging Applications of Ultrasound-Contrast Agents in Radiation Therapy.

Authors:  Quezia Lacerda; Mohamed Tantawi; Dennis B Leeper; Margaret A Wheatley; John R Eisenbrey
Journal:  Ultrasound Med Biol       Date:  2021-02-27       Impact factor: 3.694

5.  Fluorescein-mediated sonodynamic therapy in a rat glioma model.

Authors:  Francesco Prada; Natasha Sheybani; Andrea Franzini; David Moore; Diogo Cordeiro; Jason Sheehan; Kelsie Timbie; Zhiyuan Xu
Journal:  J Neurooncol       Date:  2020-06-04       Impact factor: 4.506

6.  Recent advances of sonodynamic therapy in cancer treatment.

Authors:  Guo-Yun Wan; Yang Liu; Bo-Wei Chen; Yuan-Yuan Liu; Yin-Song Wang; Ning Zhang
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

Review 7.  Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells.

Authors:  Krzysztof Bilmin; Tamara Kujawska; Paweł Grieb
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600

Review 8.  Sonodynamic therapy for gliomas.

Authors:  Adomas Bunevicius; Stylianos Pikis; Frederic Padilla; Francesco Prada; Jason Sheehan
Journal:  J Neurooncol       Date:  2021-07-12       Impact factor: 4.130

9.  Intracranial Sonodynamic Therapy With 5-Aminolevulinic Acid and Sodium Fluorescein: Safety Study in a Porcine Model.

Authors:  Luca Raspagliesi; Antonio D'Ammando; Matteo Gionso; Natasha D Sheybani; Maria-Beatriz Lopes; David Moore; Steven Allen; Jeremy Gatesman; Edoardo Porto; Kelsie Timbie; Andrea Franzini; Francesco Di Meco; Jason Sheehan; Zhiyuan Xu; Francesco Prada
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

Review 10.  Sonodynamic Therapy for the Treatment of Intracranial Gliomas.

Authors:  Antonio D'Ammando; Luca Raspagliesi; Matteo Gionso; Andrea Franzini; Edoardo Porto; Francesco Di Meco; Giovanni Durando; Serena Pellegatta; Francesco Prada
Journal:  J Clin Med       Date:  2021-03-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.